Mineralys Therapeutics (MLYS) PT Raised to $52 at Stifel on Lorundrostat Potential
Tweet Send to a Friend
Stifel analyst Annabel Samimy raised the price target on Mineralys Therapeutics, Inc. (NASDAQ: MLYS) to $52.00 (from $45.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
